Erratum to GLP-1 receptor agonists: a review of head-to-head clinical studies

Abstract

SAGE Publications wish to apologise for the following error which was introduced into "GLP-1 receptor agonists: a review of head-to-head clinical studies" by Jennifer M. Trujillo, Wesley Nuffer and Samuel L. Ellis. This article was published in Therapeutic Advances in Endocrinology and Metabolism 2015, volume 6(1) 19-28, DOI: 10.1177/2042018814559725.

Figure 1.

Change in A1C values with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in head-to-head clinical studies. p-values are for statistical superiority unless otherwise noted as non-inferiority; * p < 0.0025, † p < 0.0001, ‡ p =0.02, § p = not significant, noninferiority p-value not reported (95% confidence interval 0.033-0.297, meeting predefined non-inferiority margin), ¶ non-inferiority p-value=0.0846 (not meeting predefined non-inferiority margin), **p<0.001 for both doses of dulaglutide versus exenatide bid, †† p= not significant, non-inferiority p-value < 0.0001 (meeting predefined non-inferiority margin).

Figure 2.

Change in weight with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in head-to-head clinical studies. p-values are for statistical superiority (unless noted for non-inferiority); * p = not significant, † p = 0.0005, ‡ p-value not reported for weight difference of 1.02 kg (95% confidence interval 0.456-1.581), § p < 0.0001, ¶ p < 0.001 dulaglutide 0.75mg versus exenatide bid, ** p = not significant between dulaglutide 1.5mg versus exenatide bid,†† p = 0.011.